Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
about
Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsAssociation of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetesPoorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnosticsThe domino effect: obesity, type 2 diabetes and cardiovascular disease.The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.The effects of thiazolidinediones on blood pressure levels - a systematic review.Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approachesCardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.Biomedical imaging research opportunities workshop IV: a white paper.Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience.Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update.GenomeRunner web server: regulatory similarity and differences define the functional impact of SNP sets.The relationship between insulin sensitivity and heart rate-corrected QT interval in patients with type 2 diabetes.The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J MicePractical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
P2860
Q28238585-F2EBF262-E0FD-4900-A180-DCE6D5E0C27BQ34668321-81509BD1-F2DC-4E80-8514-8D6CC08E2F37Q35189544-8A878AB5-119A-4E1F-988C-3644BA96B8F3Q36238067-DF049F4D-3AE8-43FA-94FF-FBAC28D50707Q36507641-CC54BFB1-02EC-47A5-A4AD-05DEFF0C0F80Q36545395-A0732AAA-3343-4FCD-821D-3E8701964C9AQ36608474-5DCA2214-019A-4BB9-8AFE-D87F9F21B9F4Q36679594-FD20FC84-8E25-4669-A4AA-F9EB6C3C9E6AQ36771634-5337BB6B-B993-4A9D-9A41-89C87521B57AQ36835841-A917EB0F-D2DD-47A6-A2B7-1978489FAD2DQ36982936-5D323B9B-D915-4041-B843-5CC2922A0FC9Q37142138-2DA3A077-86F0-40CD-A6DD-46EB9C437509Q38447734-2A42DD67-12D2-4C02-92E2-333E3813CBE7Q41281402-38C12AD0-4569-4214-AB16-61E71A852F65Q42007043-A56455AD-B1DD-4E38-8D2E-4D24C2BB95A1Q47697775-2F662BEC-905D-4A6C-AD6E-1A4729B47412Q50044216-161F0975-8629-461D-9139-D6E529C71D6E
P2860
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
@ast
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
@en
type
label
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
@ast
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
@en
prefLabel
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
@ast
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
@en
P1476
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
@en
P2093
Mark W Stolar
Robert J Chilton
P356
10.1016/S0149-2918(03)80240-0
P478
25 Suppl B
P577
2003-01-01T00:00:00Z